News

MS Health Care Excellence Awards Launched in UK

UK-basedĀ MS Trust has announced the launch of newĀ awards designedĀ to distinguish healthcare professionals that are committed to treatingĀ and changing the lives of patients who suffer from multiple sclerosis (MS). The QuDos Awards are currently open for nominations and will featureĀ ten different categories. TheĀ QuDoS in MS Awards ā€“…

Novartis Pharma Program Helping Young People with MS Get And Keep Jobs

Most employers these days talk about having workforce diversity oriented policies that support hiring people living with disabilities and chronic diseases, but what distinguishes rhetoric from reality? What in positive, practical terms can companies do in support of helping people living with visible or invisible challenges find and keep gainful…

Multiple Sclerosis Community Celebrates World MS Day

World MS Day is celebrated onĀ May 27 as a day dedicated to thoseĀ who suffer fromĀ multiple sclerosis (MS). In order to mark the occasion, organizations, companies, advocates, and communities are hosting events throughout the worldĀ to share inspiring stories, raise awareness about the disease and campaign to support both patients…

AUBAGIO Included in Prince Edward Island Pharmacare

Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the drug developed and commercialized byĀ Genzyme is now financially supported by the state as aĀ first-line oral tablet to treat patients who…

Progressive MS Challenges to Be Dicussed at CMSC Meeting

The needs of patients who suffer from progressive multiple sclerosis (MS) willĀ be addressed in a presentation hosted byĀ Alan Thompson, MD, FRCP, from the University College London (UCL) duringĀ theĀ Donald Paty Memorial Lecture. The Lecture will take place during the Consortium of Multiple Sclerosis Centers (CMSC) 29th Annual…

11-Year Follow-up of Bayer’s BENEFIT Interferon-beta1b Treatment Reveals Positive Results For MS Patients

Results from the BENEFIT11 trial indicate thatĀ early treatment with IFNB-1b leads to improvements inĀ cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark. Supported byĀ Bayer HealthCare Pharmaceuticals, the study, titled “Long-term Impact of Early MS Treatment with…

Genzyme Announces New Research Collaboration With Ablynx for Innovative Multiple Sclerosis Therapeutic Project

This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate the use of Nanobodies as part of a targeted therapeutic strategy for multiple sclerosis (MS). Ā The research will utilize Genzymeā€™s early-stage MS research programs involving neuroprotection…

MSAA Organizes Make a Splash Fundraising Event for Memorial Day

The Multiple Sclerosis Association of America (MSAA) is organizing a national fundraising campaignĀ just inĀ time for summer. TheĀ Swim for MSĀ event willĀ help the association fund activities and support the multiple sclerosis (MS)Ā community with crucialĀ services to help improve the lives of the 400,000 people in the United…

Gut Bacteria: Key to MS?

There has been a great deal of recent interest in the connection between nervous system function and the complex bacteria that are found in the gastrointestinal system, known as the gut microbiome. Some scientists believe that differences in the type of bacteria found in the gut mayĀ underlie neurological disease. In…